Terms: = Prostate cancer AND hCG AND Diagnosis
24 results:
1. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
2. Urothelial carcinoma of the prostate with raised β-hcg levels: a case report.
Sołek J; Kalwas M; Sobczak M; Dębska-Szmich S; Kupnicki P; Jesionek-Kupnicka D
J Med Case Rep; 2022 Jun; 16(1):238. PubMed ID: 35701835
[TBL] [Abstract] [Full Text] [Related]
3. Tumour markers and their utility in imaging of abdominal and pelvic malignancies.
Lahoud RM; O'Shea A; El-Mouhayyar C; Atre ID; Eurboonyanun K; Harisinghani M
Clin Radiol; 2021 Feb; 76(2):99-107. PubMed ID: 32861463
[TBL] [Abstract] [Full Text] [Related]
4. Multiplex measurement of twelve tumor markers using a GMR multi-biomarker immunoassay biosensor.
Gao Y; Huo W; Zhang L; Lian J; Tao W; Song C; Tang J; Shi S; Gao Y
Biosens Bioelectron; 2019 Jan; 123():204-210. PubMed ID: 30174274
[TBL] [Abstract] [Full Text] [Related]
5. Pediatric reference intervals for 29 Ortho VITROS 5600 immunoassays using the CALIPER cohort of healthy children and adolescents.
Higgins V; Fung AWS; Chan MK; Macri J; Adeli K
Clin Chem Lab Med; 2018 Jan; 56(2):327-340. PubMed ID: 28723610
[TBL] [Abstract] [Full Text] [Related]
6. PEG-based autonomous capillary system with integrated microbead array for immunoassay.
Zhu Q; Trau D
Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 2):1031-1038. PubMed ID: 27772702
[TBL] [Abstract] [Full Text] [Related]
7. Biomarker development, from bench to bedside.
Stenman UH
Crit Rev Clin Lab Sci; 2016; 53(2):69-86. PubMed ID: 26287282
[TBL] [Abstract] [Full Text] [Related]
8. Gel pad array chip for high throughput and multi-analyte microbead-based immunoassays.
Zhu Q; Trau D
Biosens Bioelectron; 2015 Apr; 66():370-8. PubMed ID: 25463645
[TBL] [Abstract] [Full Text] [Related]
9. Carbohydrate antigens as potential biomarkers for the malignancy in patients with idiopathic deep venous thrombosis: a retrospective cohort study.
Yu M; Wang YH; Abdalla AME; Liu WQ; Mei F; Wang J; Ouyang CX; Li YQ
J Huazhong Univ Sci Technolog Med Sci; 2014 Oct; 34(5):722-728. PubMed ID: 25318883
[TBL] [Abstract] [Full Text] [Related]
10. Multiplex detection platform for tumor markers and glucose in serum based on a microfluidic microparticle array.
Zhu Q; Trau D
Anal Chim Acta; 2012 Nov; 751():146-54. PubMed ID: 23084064
[TBL] [Abstract] [Full Text] [Related]
11. [Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site].
Pejcić I; Vrbić S; Filipović S; Sćekić M; Petković I; Pejcić L; Djenić N
Vojnosanit Pregl; 2010 Sep; 67(9):723-31. PubMed ID: 20954411
[TBL] [Abstract] [Full Text] [Related]
12. Use of common seric tumor markers in patients with solid cancers.
Gara S; Boussen H; Ghanem A; Guemira F
Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
[TBL] [Abstract] [Full Text] [Related]
13. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract] [Full Text] [Related]
14. [Clinical usefulness of circulating tumor markers].
Ohkura H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
[TBL] [Abstract] [Full Text] [Related]
15. [Significance of current bio- and molecular-markers in urological cancers].
Shimazui T; Akaza H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
[TBL] [Abstract] [Full Text] [Related]
16. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract] [Full Text] [Related]
17. [Diagnostic management of inaugurable metastases].
Penel N
Presse Med; 2003 Jun; 32(21):990-6, 1004. PubMed ID: 12876530
[TBL] [Abstract] [Full Text] [Related]
18. Circulating tumor markers and nuclear medicine imaging modalities: breast, prostate and ovarian cancer.
Ugrinska A; Bombardieri E; Stokkel MP; Crippa F; Pauwels EK
Q J Nucl Med; 2002 Jun; 46(2):88-104. PubMed ID: 12114872
[TBL] [Abstract] [Full Text] [Related]
19. Doctor's dilemma: incorporating tumor markers into clinical decision-making.
Canil CM; Tannock IF
Semin Oncol; 2002 Jun; 29(3):286-93. PubMed ID: 12063682
[TBL] [Abstract] [Full Text] [Related]
20. Clinical uses of tumor markers: a critical review.
Duffy MJ
Crit Rev Clin Lab Sci; 2001 Jun; 38(3):225-62. PubMed ID: 11451209
[TBL] [Abstract] [Full Text] [Related]
[Next]
